Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Treating breast cancer in the 21st century: emerging biological therapies.

Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ.

J Cancer. 2013;4(2):117-32. doi: 10.7150/jca.4925. Epub 2013 Jan 11.

2.

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.

PMID:
24080156
3.

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Chung C, Lam MS.

Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735. Review.

PMID:
23988598
4.

Recent advances in novel targeted therapies for HER2-positive breast cancer.

Murphy CG, Morris PG.

Anticancer Drugs. 2012 Sep;23(8):765-76. doi: 10.1097/CAD.0b013e328352d292. Review.

PMID:
22824822
5.

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.

Gradishar WJ.

Ann Oncol. 2013 Oct;24(10):2492-500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4. Review.

PMID:
23827380
6.

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN.

Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3. Review.

7.

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini KS, Azim HA Jr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart M.

Breast. 2011 Oct;20 Suppl 3:S20-7. doi: 10.1016/S0960-9776(11)70289-2. Review.

PMID:
22015288
8.

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.

Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.

9.

HER2-positive breast cancer: current and future treatment strategies.

Engel RH, Kaklamani VG.

Drugs. 2007;67(9):1329-41. Review.

PMID:
17547474
10.

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Awada A, Bozovic-Spasojevic I, Chow L.

Cancer Treat Rev. 2012 Aug;38(5):494-504. doi: 10.1016/j.ctrv.2012.01.001. Epub 2012 Feb 3. Review.

PMID:
22305205
11.

Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.

Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.

Cytometry A. 2011 Sep;79(9):684-93. doi: 10.1002/cyto.a.21107. Epub 2011 Jul 22.

12.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
13.

Recent developments in treatment stratification for metastatic breast cancer.

Barton S, Swanton C.

Drugs. 2011 Nov 12;71(16):2099-113. doi: 10.2165/11594480-000000000-00000. Review.

PMID:
22035512
14.

HER2 breast cancer therapies: a review.

Murphy CG, Modi S.

Biologics. 2009;3:289-301. Epub 2009 Jul 13.

15.

Dual HER2-targeted approaches in HER2-positive breast cancer.

Ahn ER, Vogel CL.

Breast Cancer Res Treat. 2012 Jan;131(2):371-83. doi: 10.1007/s10549-011-1781-y. Epub 2011 Sep 29. Review.

PMID:
21956210
16.

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Review.

PMID:
23881722
17.

Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

Sachdev JC, Jahanzeb M.

Clin Breast Cancer. 2012 Feb;12(1):19-29. doi: 10.1016/j.clbc.2011.07.001. Epub 2011 Sep 8. Review.

PMID:
21903480
18.

Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

Esteva FJ, Pusztai L.

Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.

19.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
20.

Co-targeting estrogen receptor and HER2 pathways in breast cancer.

Mehta A, Tripathy D.

Breast. 2014 Feb;23(1):2-9. doi: 10.1016/j.breast.2013.09.006. Epub 2013 Oct 28. Review.

PMID:
24176518

Supplemental Content

Support Center